Eli Lilly is cutting insulin prices, and this time it’s for real.
Months after a Twitter account posing as the drugmaker went viral with a tweet stating, “insulin is free now,” the company on Wednesday…
Friedrich’s ataxia, an ultra-rare disease that causes progressively worsening muscle function that ultimately leads to death, now has its first FDA-approved therapy. The regulator has given the green light to a Reata Pharmaceuticals drug…
Continue Reading
Aptinyx’s approach of treating neurological disorders by targeting a key receptor in the brain has fallen short again, this time in Parkinson’s disease. With its third clinical trial failure in less than a year,…
Continue Reading
Generic drugs giant Dr. Reddy’s is acquiring the U.S portfolio of Mayne Pharma in a deal that includes a birth control pill Mayne has described as its most significant product opportunity.
Under deal terms announced…
Cough, fever, and breathing difficulty could signal a Covid-19 infection. It could also be the flu. A Lucira Health diagnostic is now the first one authorized by the FDA to identify the culprit virus…
Continue Reading
A Fulcrum Therapeutics clinical trial testing a potential sickle cell disease drug has been paused by the FDA. With the clinical hold on the early-stage study, Fulcrum becomes the fourth company with a stalled…
Continue Reading
Hemophilia A patients manage the chronic disorder with infusions administered as frequently as every two to three days. The FDA has approved a Sanofi drug designed to last longer in the body, giving patients…
Continue Reading
The vast majority of the critically essential secrets in biology are hidden from researchers. The human microbiome is now considered a human organ, yet the word “microbiome” was not in the research lexicon as…
Continue Reading
Each person is unique in how they react to prescription and over-the-counter medications. Factors like genetics and other medications you take can affect how you metabolize and respond to certain drugs. Understanding these factors…
Continue Reading
AbbVie turned to Capsida Biotherapeutics two years ago for help delivering gene therapies into the brain. That partnership is ongoing, but the pharmaceutical giant now wants to leverage its partner’s technology for delivery of…
Continue Reading
